Terns Pharmaceuticals Valuation
| TERN Stock | USD 37.77 2.43 6.88% |
At this time, the company appears to be undervalued. Terns Pharmaceuticals has a current Real Value of $44.17 per share. The regular price of the company is $37.77. Our model measures the value of Terns Pharmaceuticals from inspecting the company fundamentals such as Shares Outstanding of 108.77 M, return on equity of -0.29, and Shares Owned By Institutions of 85.80 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Terns Pharmaceuticals' valuation include:
Price Book 14.4619 | Enterprise Value | Enterprise Value Ebitda (5.80) | Price Sales 302.636 | Enterprise Value Revenue 337.4686 |
Undervalued
Today
Please note that Terns Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Terns Pharmaceuticals is based on 3 months time horizon. Increasing Terns Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Terns Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Terns Stock. However, Terns Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 37.77 | Real 44.17 | Target 58.13 | Hype 38.68 |
The intrinsic value of Terns Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Terns Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Terns Pharmaceuticals helps investors to forecast how Terns stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Terns Pharmaceuticals more accurately as focusing exclusively on Terns Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Terns Pharmaceuticals' intrinsic value based on its ongoing forecasts of Terns Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Terns Pharmaceuticals' closest peers.
Terns Pharmaceuticals Cash |
|
Terns Pharmaceuticals Total Value Analysis
Terns Pharmaceuticals is at this time projected to have valuation of 3.81 B with market capitalization of 4.11 B, debt of 1.35 M, and cash on hands of 139.81 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Terns Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.81 B | 4.11 B | 1.35 M | 139.81 M |
Terns Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Terns is to check how much profit was generated for every dollar of assets it reports. Terns Pharmaceuticals has a negative utilization of assets of -0.2 %, losing $0.001994 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Terns Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Terns Pharmaceuticals Profitability Analysis
Based on Terns Pharmaceuticals' profitability indicators, Terns Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Terns Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-12-31 | Previous Quarter -24.1 M | Current Value -24.6 M | Quarterly Volatility 6.9 M |
For Terns Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Terns Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Terns Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Terns Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Terns Pharmaceuticals over time as well as its relative position and ranking within its peers.
Terns Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Terns Pharmaceuticals is estimated to be -0.3033 with future projections ranging from a low of -0.34 to a high of -0.25. Terns Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -1.02. Please be aware that the consensus of earnings estimates for Terns Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Terns Pharmaceuticals Earnings Estimation Breakdown
The calculation of Terns Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Terns Pharmaceuticals is estimated to be -0.3033 with the future projection ranging from a low of -0.34 to a high of -0.25. Please be aware that this consensus of annual earnings estimates for Terns Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.34 Lowest | Expected EPS | -0.25 Highest |
Terns Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Terns Pharmaceuticals' value are higher than the current market price of the Terns Pharmaceuticals stock. In this case, investors may conclude that Terns Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Terns Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 10 | 50.0% | 0.0 | -0.3033 | -1.02 |
Terns Pharmaceuticals Ownership Allocation
Terns Pharmaceuticals shows a total of 108.77 Million outstanding shares. The majority of Terns Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Terns Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Terns Pharmaceuticals. Please pay attention to any change in the institutional holdings of Terns Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Terns Pharmaceuticals Profitability Analysis
Net Loss for the year was (88.85 M) with profit before overhead, payroll, taxes, and interest of 1000 K.About Terns Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Terns Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Terns Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Terns Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Terns Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Terns Pharmaceuticals. We calculate exposure to Terns Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Terns Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -792.9 K | -753.3 K | |
| Pretax Profit Margin | (44.68) | (46.92) | |
| Operating Profit Margin | (44.87) | (47.12) | |
| Net Loss | (45.14) | (47.40) |
Terns Pharmaceuticals Current Valuation Indicators
Terns Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Terns Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Terns Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Terns Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Terns Pharmaceuticals' worth.When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Will Pharmaceuticals sector continue expanding? Could Terns diversify its offerings? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Terns Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Terns Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Terns's accounting equity. The concept of intrinsic value - what Terns Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Terns Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Terns Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.